Compare American Tower Corp (AMT) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American Tower Corp vs Merck & Co., Inc. — how do they compare? American Tower Corp trades at $169 (market cap $78.54B), while Merck & Co., Inc. trades at $123.99 (market cap $305.12B). The key difference: Merck & Co., Inc. is far larger — about 3.9× American Tower Corp's market cap, and American Tower Corp pays the higher dividend (4.14%). Which is the better fit depends on your goals.
| AMT | MRK | |
|---|---|---|
Market Cap | $78.54B | $305.12B |
Sector | Real Estate | Health |
52-Week High | $232.35 | $129.52 |
52-Week Low | $162.11 | $77.60 |
Enterprise Value | $122.07B | $348.54B |
Dividend Yield | 4.14% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Tower (AMT) trades at $168.59, up 2.18% today, with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals including a 26.81% net margin and 82.19% ROE. Recent news highlights its data center growth and sustainability initiatives, while analyst consensus remains strongly bullish with a $214.10 price target.
AMT presents a compelling long-term investment opportunity given its high profitability, dividend yield, and market leadership, though elevated debt levels and near-term technical weakness pose risks. Upside potential exists if the company continues executing on 5G and data center expansion, but investors should monitor interest rate sensitivity and competitive pressures.
Merck (MRK) trades at $123.54, down 1.22% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $136.38. Recent earnings have consistently beaten expectations, with Q1 2026 showing a smaller loss than forecast. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while strong profitability metrics like a 73.91% gross margin and 18.97% ROE highlight operational efficiency.
The outlook remains positive given analyst support and strategic M&A, but risks include rising debt levels and patent expirations. Revenue growth is steady, though 2026 net income is projected to decline. Investors should weigh the stock's premium valuation against its robust dividend and pipeline expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Tower Corp
American Tower owns and operates more than 220,000 cell towers throughout the U.S., Asia, Latin America, Europe, and Africa. It also owns and/or operates 25 data centers in eight U.S. markets after acquiring CoreSite. On its towers, the company has a very concentrated customer base, with most revenue in each market being generated by just the top few mobile carriers. The company operates more than 40,000 towers in the U.S., which accounted for more than half of its total revenue in 2021. Outside the U.S., American Tower's greatest presence is in India and Brazil, where it operates roughly 75,000 and 19,000 towers, respectively. American Tower operates as a real estate investment trust.
Read more on AMT →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
